Indication
Stage IIIA Breast Cancer
47 clinical trials
52 products
23 drugs
Clinical trial
A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Bintrafusp AlfaClinical trial
Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast CancerStatus: Completed, Estimated PCD: 2023-12-31
Drug
AlpelisibProduct
EnzalutamideClinical trial
Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast SurgeryStatus: Active (not recruiting), Estimated PCD: 2021-02-22
Product
EndoxifenClinical trial
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2025-02-28
Drug
CisplatinClinical trial
ARTEMIS: A Robust TNBC Evaluation FraMework to Improve SurvivalStatus: Recruiting, Estimated PCD: 2026-11-30
Clinical trial
Phase II Trial of Rifaximin in Patients With Early Stage HER2 Positive Breast Cancer With Gastrointestinal Toxicities Related to Pertuzumab-Based TherapyStatus: Active (not recruiting), Estimated PCD: 2022-12-27
Product
RifaximinClinical trial
A Phase I, Single Arm, Prospective Study to Evaluate the Treatment of Genitourinary Syndrome of Menopause With Platelet Rich Plasma (PRP) in Women With a History of Breast CancerStatus: Completed, Estimated PCD: 2024-01-10
Clinical trial
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-06-22
Product
CediranibClinical trial
A Phase 1b Study of Neratinib, Pertuzumab, and Trastuzumab With Taxol (3HT) in Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBCStatus: Active (not recruiting), Estimated PCD: 2026-01-01
Drug
cyclophosphamideDrug
R-CHOPProduct
NeratinibClinical trial
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxStatus: Recruiting, Estimated PCD: 2026-09-01
Drug
AtezolizumabProduct
CabozantinibDrug
TiragolumabProduct
PertuzumabDrug
TrastuzumabProduct
OlaparibClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
AbraxaneClinical trial
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Triple Negative Breast Cancer (TNBC)Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
IpilimumabProduct
PembrolizumabProduct
Vaccine TherapyClinical trial
A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Phase 1B Trial Evaluating the Safety of Ribociclib, Tucatinib, and Trastuzumab in Patients With Metastatic, HER2+ Breast Cancer and a Multicenter, Randomized, Open-Label, Phase 2 Study of Preoperative Treatment With Ribociclib,Ttrastuzumab, Tucatinib, and Fulvestrant Versus Docetaxel, Carboplatin,Ttrastuzumab, and Pertuzumab in HR+/HER2+ Breast Cancer and Ribociclib, Trastuzumab, and Tucatinib Versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients With HR-/HER2+ Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-01
Product
CarboplatinProduct
Neoantigen Peptide VaccineDrug
DocetaxelProduct
FulvestrantProduct
RibociclibDrug
TucatinibClinical trial
Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Product
FamotidineProduct
CimetidineProduct
DexamethasoneClinical trial
Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast CancerStatus: Completed, Estimated PCD: 2024-04-17
Product
HydroxychloroquineProduct
LetrozoleProduct
PalbociclibProduct
DiphenhydramineClinical trial
Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)Status: Recruiting, Estimated PCD: 2024-07-31
Product
AbemaciclibClinical trial
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast CancerStatus: Completed, Estimated PCD: 2019-01-31
Drug
AN0025Clinical trial
Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2025-03-31
Drug
CeralasertibProduct
TremelimumabClinical trial
Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Locally Advanced or Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2017-05-17
Clinical trial
A Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer SurvivorsStatus: Recruiting, Estimated PCD: 2024-11-01
Product
Anhydrous Enol-oxaloacetateProduct
RanitidineClinical trial
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to DocetaxelStatus: Active (not recruiting), Estimated PCD: 2022-07-25
Product
AZD8186Clinical trial
Pharmacodynamic Study of Estrogen Suppression Threshold-Directed Therapy (ESTDT) of Anastrozole as Adjuvant Therapy for Early Stage Breast CancerStatus: Completed, Estimated PCD: 2022-12-12
Product
AnastrozoleClinical trial
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American WomenStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2025-08-31
Product
PanitumumabClinical trial
A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast CancerStatus: Completed, Estimated PCD: 2023-11-15
Clinical trial
A Pilot Trial of Preoperative Oral Microbiota-Based Investigational New Drug, RBX7455 to Target Immune Response in Patients With Operable Stage I-III Breast CancerStatus: Terminated, Estimated PCD: 2023-01-11
Product
RBX7455Clinical trial
Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2022-05-19
Product
BinimetinibDrug
mFOLFOX6Clinical trial
An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without TrastuzumabStatus: Completed, Estimated PCD: 2022-10-31
Product
LoperamideClinical trial
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-11-06
Product
TamoxifenClinical trial
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast CancerStatus: Active (not recruiting), Estimated PCD: 2014-08-01
Clinical trial
Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC)Status: Withdrawn, Estimated PCD: 2023-07-26
Clinical trial
A Phase II Study of Concurrent WOKVAC Vaccination With Neoadjuvant Chemotherapy and HER2-Targeted Monoclonal Antibody TherapyStatus: Recruiting, Estimated PCD: 2024-10-30
Product
pUMVC3-IGFBP2-HER2-IGF1RClinical trial
A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deletedStatus: Terminated, Estimated PCD: 2023-05-17
Drug
LurbinectedinClinical trial
A Phase II Trial of The Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDC25B, CD105) in Participants With Early Stage Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-30
Drug
GM-CSFDrug
T-VECProduct
Talimogene LaherparepvecClinical trial
A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Chemotherapy or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Drug
TucidinostatProduct
ExemestaneDrug
AlpelisibClinical trial
Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure EstimationStatus: Recruiting, Estimated PCD: 2026-05-31
Drug
TamoxifenProduct
Nab paclitaxelDrug
GemcitabineClinical trial
A Phase Ib/II Study of the Safety and Pharmacology of Nilotinib to Prevent Paclitaxel-Induced Peripheral Neuropathy in Patients With Breast CancerStatus: Recruiting, Estimated PCD: 2024-01-02
Product
NilotinibClinical trial
Atorvastatin in Triple-Negative Breast Cancer (TNBC) Patients Who Did Not Achieve a Pathologic Complete Response (pCR) After Receiving Neoadjuvant Chemotherapy, a Multicenter Pilot StudyStatus: Completed, Estimated PCD: 2023-10-19
Drug
AtorvastatinClinical trial
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and TucatinibStatus: Recruiting, Estimated PCD: 2028-01-01
Product
Trastuzumab EmtansineDrug
UTD1Product
PlaceboClinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Product
IrinotecanProduct
VeliparibClinical trial
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete ResponseStatus: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver DysfunctionStatus: Active (not recruiting), Estimated PCD: 2018-11-29
Product
RomidepsinClinical trial
A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Product
ALRN-6924Clinical trial
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Drug
cetuximabProduct
TemsirolimusProduct
Valproic AcidClinical trial
Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast CancerStatus: Active (not recruiting), Estimated PCD: 2014-01-31
Product
LapatinibClinical trial
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2017-07-31